| ADCYAP1 |
| LOCUS ID | 116 | |||||||||||||
| GENE_SYMBOL | ADCYAP1 | |||||||||||||
| GENE NAME | adenylate cyclase ac | |||||||||||||
| SYNONYMNS | PACAP | |||||||||||||
| CHROMOSOME | 18 | |||||||||||||
| HOMOLOGENE ID | 869 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| This gene encodes a secreted proprotein that is further processed into multiple mature peptides. These peptides stimulate adenylate cyclase and increase cyclic adenosine monophosphate (cAMP) levels, resulting in the transcriptional activation of target genes. The products of this gene are key mediators of neuroendocrine stress responses. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2013] |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Nephropathy | 1. To conclude, PACAP is effective in ameliorating diabetic nephropathy at least partly through its well-known anti-inflammatory effect.2. These raise the opportunity for the use of PACAP as a possible therapeutic or preventive method in treating the complications of diabetes. 3. We conclude that the nephroprotective effect of PACAP in diabetes is, at least partly, due to its antiapoptotic, antifibrotic and antioxidative effect in addition to the previously described antiinflammatory effect. | 23416022 |
| Retinopathy | 1. These suggest that PACAP has a therapeutic potential in diabetic retinopathy. 2. Inhibition of apoptosis is one of the PACAP-induced pathways with therapeutic potential in early experimental diabetic retinopathy. | 22350850 |